Deltex Medical Group PLC US launch of TrueVue(TM) system
October 24 2017 - 2:00AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
24 October 2017
24 October 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
US launch of TrueVue(TM) system
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the
launch this week of its revolutionary concept in advanced
haemodynamic monitoring, the TrueVue(TM) system.
The TrueVue(TM) system comprises three distinct best-in-class
advanced haemodynamic monitoring technologies on a single platform
(the CardioQ-ODM+):
- TrueVue(TM) Doppler: high-end ODM technology providing beat-to-beat
imaging of cardiac output for monitoring sedated patients and
easy calibration/recalibration of arterial pressure cardiac
output
- TrueVue(TM) Impedance: non-invasive, high definition impedance
cardiography for monitoring awake patients, both mobile and
immobile
- TrueVue(TM) Loops: unique real-time biomarkers for early detection
of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time
display of responses to treatment
The TrueVue(TM) system is being featured at Deltex's booth at
Anesthesiology 2017, the annual meeting of the American Society of
Anesthesiologists in Boston, MA. This is the largest anaesthesia
conference in the USA and is attended by large numbers of
international delegates as well as thousands of doctors from across
the USA.
Use of TrueVue(TM) Impedance in the USA is subject to FDA
approval: the submission (510K) has been submitted and not yet
granted.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"The launch of the TrueVue(TM) system on the CardioQ-ODM+
platform is an exciting development for the Company. It means we
will now be marketing the world's first haemodynamic monitoring
system which can be used across the whole patient pathway from
awake, mobile outpatients of all ages through to sedated, critical
care patients. The TrueVue(TM) system can be used by trainee staff,
in non-critical situations, through to experienced specialists. It
will also broaden the Company's addressable market and positions us
to supply hospitals with all their haemodynamic monitoring
requirements on a single platform."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable products.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEASEDALXXFFF
(END) Dow Jones Newswires
October 24, 2017 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024